info:eu-repo/semantics/article
Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
Registro en:
Zapata-Cardona MI, Flórez-Álvarez L, Lopera TJ, Chvatal-Medina M, Zapata-Builes W, Diaz FJ, Aguilar-Jimenez W, Taborda N, Hernandez JC, Rugeles MT. Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia. Front Immunol. 2022 Dec 21;13:1102384. doi: 10.3389/fimmu.2022.1102384. PMID: 36618393; PMCID: PMC9811190.
1664-3224
10.3389/fimmu.2022.1102384
1664-3224
Autor
Zapata Cardona, María Isabel
Flórez Álvarez, Lizdany
Lopera Restrepo, Tulio José
Medina Chvatal, Mateo
Zapata Builes, Wildeman
Díaz Castrillón, Francisco Javier
Aguilar Jiménez, Wbeimar
Taborda Vanegas, Natalia Andrea
Hernández López, Juan Carlos
Rugeles López, María Teresa
Institución
Resumen
ABSTRACT:The emergence of the Omicron variant has generated concerns about the efficacy
of COVID-19 vaccines. We evaluated the serum neutralizing activity of antibodies
against the Omicron (lineage BA.1.1) by plaque reduction neutralizing test, as well as
its correlation with age and gender, in a Colombian cohort six months after being
vaccinated with BNT162b2 (Pfizer/BioNTech). Compared to all other variants
analyzed, a significantly lower neutralizing activity (p<0.001) was observed against
Omicron. Interestingly, older individuals exhibited lower titers against Omicron than
those younger than 40. No statistical differences in neutralizing activity were
observed according to gender. Our results showed that two doses of BNT162b2
might not provide robust protection against the Omicron variant over time. It is
necessary to consider including changes in the composition of the vaccines to
protect against new emerging variants of SARS-CoV-2 and campaigns to
implement additional booster vaccinations COL0012444